JP2012511014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012511014A5 JP2012511014A5 JP2011539720A JP2011539720A JP2012511014A5 JP 2012511014 A5 JP2012511014 A5 JP 2012511014A5 JP 2011539720 A JP2011539720 A JP 2011539720A JP 2011539720 A JP2011539720 A JP 2011539720A JP 2012511014 A5 JP2012511014 A5 JP 2012511014A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- compound
- cd40l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001123 antibodies Proteins 0.000 claims 20
- 102000004965 antibodies Human genes 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 9
- 102100019461 CD28 Human genes 0.000 claims 6
- 101700033362 CD28 Proteins 0.000 claims 6
- 230000003993 interaction Effects 0.000 claims 5
- 230000035693 Fab Effects 0.000 claims 4
- 102100019451 CD80 Human genes 0.000 claims 3
- 101700080477 CD80 Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 102100013137 CD40 Human genes 0.000 claims 2
- 101710040446 CD40 Proteins 0.000 claims 2
- 108010029697 CD40 Ligand Proteins 0.000 claims 2
- 102100003729 CD40LG Human genes 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 102100007495 AR Human genes 0.000 claims 1
- 101700046185 AR Proteins 0.000 claims 1
- 108010061171 Abatacept Proteins 0.000 claims 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
- 201000008166 Kennedy's disease Diseases 0.000 claims 1
- 206010065579 Multifocal motor neuropathy Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 208000006883 Neuromuscular Disease Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 208000002320 Spinal Muscular Atrophy Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 102000037240 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
Claims (13)
- 神経変性障害または神経筋障害を有する患者を治療するための、治療上有効量のＣＤ４０およびＣＤ４０Ｌの相互作用を遮断する化合物を含む、医薬組成物。
- 化合物が抗ＣＤ４０Ｌ抗体もしくは抗ＣＤ４０抗体；または抗ＣＤ４０Ｌ抗体もしくは抗ＣＤ４０抗体の抗体フラグメントである、請求項１に記載の医薬組成物。
- 化合物が、Ｆａｂ、Ｆ（ａｂ’）２、もしくはＦ（ａｂ’）抗体フラグメント；一本鎖抗体；またはＦａｂ、Ｆ（ａｂ’）２、もしくはＦ（ａｂ’）抗体フラグメントまたは一本鎖抗体の融合構築体である、請求項１または２に記載の医薬組成物。
- 抗体が、ＭＲ１、５ｃ８、ＩＤＥＣ １３１／Ｅ６０４０、クローン２４−３１、ＡＢＩ７９３、ＩｍｘＭ９０、ＩｍｘＭ９１、ＩｍｘＭ９２またはＳｇｎ−４０、およびそれらの抗体フラグメントからなる群から選択される抗ＣＤ４０Ｌ抗体である、請求項２に記載の医薬組成物。
- 抗体フラグメントが、Ｆａｂ、Ｆ（ａｂ’）２、もしくはＦ（ａｂ’）フラグメント、一本鎖抗体；または、抗体のＦａｂ、Ｆ（ａｂ’）２、もしくはＦ（ａｂ’）フラグメントもしくは一本鎖抗体の融合構築体である、請求項４に記載の医薬組成物。
- 抗ＣＤ４０Ｌ抗体が、ＭＲ１またはその抗体フラグメントである、請求項４に記載の医薬組成物。
- 抗ＣＤ４０Ｌ抗体が、５ｃ８またはその抗体フラグメントである、請求項４に記載の医薬組成物。
- 化合物が小分子である、請求項１に記載の医薬組成物。
- 治療上有効量のＣＤ４０およびＣＤ４０Ｌの相互作用を遮断する化合物を、さらに、ＣＤ２８およびＣＤ８６の間またはＣＤ２８およびＣＤ８０の間の相互作用を遮断する化合物と組み合わせて含む、請求項１−８のいずれか一項記載の医薬組成物。
- ＣＤ２８およびＣＤ８６の間またはＣＤ２８およびＣＤ８０の間の相互作用を遮断する化合物が、ＣＴＬＡ４−Ｉｇ融合タンパク質である、請求項９に記載の医薬組成物。
- ＣＤ２８およびＣＤ８６の間またはＣＤ２８およびＣＤ８０の間の相互作用を遮断する化合物が、アバタセプト、ベラタセプトまたはグリキシマブである、請求項９に記載の医薬組成物。
- 障害が、パーキンソン病、筋萎縮性側索硬化症、多巣性運動ニューロパチー、原発性側索硬化症、脊髄性筋萎縮症、ケネディ病または脊髄小脳失調症である、請求項１−１１のいずれか一項記載の医薬組成物。
- 障害が筋萎縮性側索硬化症である、請求項１２に記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12012108P | 2008-12-05 | 2008-12-05 | |
| US61/120,121 | 2008-12-05 | ||
| PCT/US2009/066715 WO2010065819A1 (en) | 2008-12-05 | 2009-12-04 | Method for the treatment of neurodegenerative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015095123A Division JP6027646B2 (ja) | 2008-12-05 | 2015-05-07 | 神経変性疾患を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012511014A JP2012511014A (ja) | 2012-05-17 |
| JP2012511014A5 true JP2012511014A5 (ja) | 2013-01-31 |
Family
ID=41824732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011539720A Pending JP2012511014A (ja) | 2008-12-05 | 2009-12-04 | 神経変成疾患を治療する方法 |
| JP2015095123A Active JP6027646B2 (ja) | 2008-12-05 | 2015-05-07 | 神経変性疾患を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015095123A Active JP6027646B2 (ja) | 2008-12-05 | 2015-05-07 | 神経変性疾患を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8435514B2 (ja) |
| EP (1) | EP2367849B1 (ja) |
| JP (2) | JP2012511014A (ja) |
| DK (1) | DK2367849T3 (ja) |
| ES (1) | ES2650267T3 (ja) |
| WO (1) | WO2010065819A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9044459B2 (en) * | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| WO2012125569A2 (en) | 2011-03-11 | 2012-09-20 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd40 antibodies and uses thereof |
| CN113461819B (zh) | 2011-04-29 | 2024-01-02 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| DK2914627T3 (da) | 2012-10-30 | 2021-07-12 | Apexigen Inc | Anti-cd40-antistoffer og fremgangsmåder til anvendelse |
| GB201501613D0 (en) * | 2015-01-30 | 2015-03-18 | Ucb Biopharma Sprl | Treatment of autoimmune disorders with CD154 antibodies |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| AU2016315873B2 (en) | 2015-09-04 | 2022-08-18 | Primatope Therapeutics Inc. | Humanized anti-CD40 antibodies and uses thereof |
| DK3359688T3 (da) | 2015-10-05 | 2021-08-23 | Biogen Ma Inc | Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme |
| MA50435A (fr) | 2017-05-24 | 2020-09-02 | Als Therapy Development Inst | Anticorps anti-ligand anti-cd40 thérapeutiques |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| TR199902192T2 (xx) | 1997-01-10 | 1999-12-21 | Biogen,Inc | Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri |
| TR199902191T2 (xx) | 1997-01-10 | 1999-12-21 | Biogen, Inc. | Anti-CD40L bile�ikleri ile lupus nefritis tedavisi |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| WO2001083755A2 (en) | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| AU2001287041B2 (en) | 2000-09-01 | 2006-06-08 | Biogen Idec Ma Inc. | Pyridine derivatives useful as CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| US20040146949A1 (en) | 2002-10-25 | 2004-07-29 | Jun Tan | Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| RU2346996C2 (ru) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Усовершенствованное выщелачивание основных металлов |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2006138316A2 (en) | 2005-06-14 | 2006-12-28 | Biogen Idec Ma Inc. | Methods for delivering molecules to the central nervous system |
-
2009
- 2009-12-04 US US13/132,670 patent/US8435514B2/en active Active
- 2009-12-04 EP EP09768576.2A patent/EP2367849B1/en active Active
- 2009-12-04 DK DK09768576.2T patent/DK2367849T3/en active
- 2009-12-04 JP JP2011539720A patent/JP2012511014A/ja active Pending
- 2009-12-04 ES ES09768576.2T patent/ES2650267T3/es active Active
- 2009-12-04 WO PCT/US2009/066715 patent/WO2010065819A1/en active Application Filing
-
2015
- 2015-05-07 JP JP2015095123A patent/JP6027646B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012511014A5 (ja) | ||
| HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
| JP2009535021A5 (ja) | ||
| JP2010526028A5 (ja) | ||
| JP2018520650A5 (ja) | ||
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| JP2010532764A5 (ja) | ||
| WO2006089133A8 (en) | Anti-cd19 antibodies and uses in oncology | |
| JP2008516970A5 (ja) | ||
| JP2016537966A5 (ja) | ||
| JP2013520996A5 (ja) | ||
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| WO2007062245A3 (en) | Human monoclonal antibody human cd134 (ox40) and methods of making and using same | |
| WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
| JP2011514150A5 (ja) | ||
| NZ594315A (en) | Antibody molecules having specificity for human ox40 | |
| WO2006099875A8 (en) | Antibodies against cd38 for treatment of multiple myeloma | |
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| JP2013538553A5 (ja) | ||
| WO2008156713A3 (en) | Anti-cd20 therapeutic compositions and methods | |
| TW200740844A (en) | Novel MAdCAM antibodies | |
| MX2009012950A (es) | ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS. | |
| JP2016513682A5 (ja) | ||
| JP2012502649A5 (ja) | ||
| WO2006128103A3 (en) | Humanized anti-cd40 antibodies and their methods of use |